Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase I dose-escalation study of intravenous PPMX-T003 in polycythemia vera
jRCT2051210083Phase 1Completed
- Sponsor
- Perseus Proteomics Inc.
- Start
- Jul 2022
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of PPMX-T003 in polycythemia vera (PV), sponsored by Perseus Proteomics Inc. Primary endpoint: Treatment-emergent adverse events. Started Jul 2022; status: completed.
02
Drugs
PPMX-T003
03
Conditions
polycythemia vera (PV)
Beyond the preview
Go deeper on jRCT2051210083.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2051210083.